Mataró Daniel, García Désirée, Coll Oriol, Vassena Rita, Rodríguez Amelia
Clínica EUGIN, Travessera de Les Corts 322, Barcelona 08029, Spain.
Fundació Privada EUGIN, Travessera de Les Corts 314, Barcelona 08029, Spain.
Hum Reprod Open. 2017 Nov 1;2017(3):hox019. doi: 10.1093/hropen/hox019. eCollection 2017.
Are the reproductive outcomes of HIV-infected donor oocyte recipient women comparable to those of non-infected women?
HIV-infected women have lower clinical pregnancy and live birth rates than non-infected women.
The literature on the effect of HIV infection on reproductive outcome is scarce at best; the only report to date comparing oocyte donation cycles in HIV-infected women versus non-infected controls found no differences in pregnancy rates between the two groups. However, this study was performed nearly a decade ago and did not evaluate the effect of immuno-virological characteristics of oocyte recipients or the HIV antiretroviral therapy effect.
This is a matched-cohort study including 514 oocyte donation cycles, 257 from HIV-infected women and 257 non-infected controls, performed between April 2004 and November 2014.
PARTICIPANTS/MATERIALS SETTING AND METHOD: Each cycle of an HIV-infected woman ( = 257) was matched with a cycle of a non-infected woman (1:1). Biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live birth in the two groups were compared using a multivariate logistic regression analysis. The effect of antiretroviral treatment options on pregnancy outcomes of HIV-infected women was analyzed using a logistic regression model adjusted for time elapsed from diagnosis, and CD4 levels and viral load prior to embryo transfer.
Cycles of HIV-infected patients receiving oocyte donation presented lower pregnancy and live birth rates than matched non-infected controls. Treatment options and infection parameters analyzed do not seem to affect the reproductive results in HIV-infected women. The variable most influencing pregnancy outcomes was the number of transferred embryos; lower pregnancy rates were obtained after single embryo transfer.
Patients with HIV infection have specific health issues, such as infection/treatment side effects, which makes it impossible to find a matching control group of non-infected patients for these variables.
HIV-infected women receiving donated oocytes present lower pregnancy rates when compared to non-infected controls, regardless of the antiretroviral treatment followed. The complexity of the treatments (both in medication types and combinations) makes it difficult to define whether any one treatment option is better than the others in terms of pregnancy outcomes in oocyte recipients.
STUDY FUNDING/COMPETING INTERESTS: None.
Not applicable.
感染人类免疫缺陷病毒(HIV)的供卵受者女性的生殖结局与未感染女性的生殖结局是否具有可比性?
感染HIV的女性的临床妊娠率和活产率低于未感染女性。
关于HIV感染对生殖结局影响的文献极为匮乏;迄今为止,唯一一项比较感染HIV女性与未感染对照者卵母细胞捐赠周期的报告发现,两组之间的妊娠率没有差异。然而,这项研究是在近十年前进行的,并未评估卵母细胞受者免疫病毒学特征的影响或HIV抗逆转录病毒疗法的效果。
研究设计、规模与持续时间:这是一项匹配队列研究,纳入了2004年4月至2014年11月期间进行的514个卵母细胞捐赠周期,其中257个来自感染HIV的女性,257个为未感染对照者。
参与者/材料、设置与方法:将每位感染HIV女性的一个周期(n = 257)与一位未感染女性的一个周期进行1:1匹配。采用多因素逻辑回归分析比较两组的生化妊娠、临床妊娠、持续妊娠和活产情况。使用经诊断后经过时间、胚胎移植前CD4水平和病毒载量校正的逻辑回归模型分析抗逆转录病毒治疗方案对感染HIV女性妊娠结局的影响。
接受卵母细胞捐赠的感染HIV患者的周期妊娠率和活产率低于匹配的未感染对照者。所分析的治疗方案和感染参数似乎不影响感染HIV女性的生殖结果。对妊娠结局影响最大的变量是移植胚胎数量;单胚胎移植后妊娠率较低。
局限性、谨慎的理由:感染HIV 的患者存在特定的健康问题,如感染/治疗副作用,这使得无法针对这些变量找到未感染患者的匹配对照组。
与未感染对照者相比,接受捐赠卵母细胞的感染HIV女性的妊娠率较低,无论采用何种抗逆转录病毒治疗。治疗的复杂性(包括药物类型和组合)使得难以确定就卵母细胞受者的妊娠结局而言,任何一种治疗方案是否优于其他方案。
研究资金/利益冲突:无。
不适用。